Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) - Total Liabilities
Based on the latest financial reports, Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD) has total liabilities worth $3.26 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Hong Kong Pharma Digital Technology Hold to evaluate the company's liquid asset resilience ratio.
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares - Total Liabilities Trend (2023–2026)
This chart illustrates how Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see HKPD total assets.
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares Competitors by Total Liabilities
The table below lists competitors of Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bladeranger Ltd
TA:BLRN
|
Israel | ILA13.36 Million |
|
Comperia.pl S.A.
WAR:CPL
|
Poland | zł12.86 Million |
|
Bri-Chem Corp.
TO:BRY
|
Canada | CA$20.68 Million |
|
Gibb River Diamonds Ltd
AU:GIB
|
Australia | AU$196.15K |
|
Celtic plc
LSE:CCPC
|
UK | GBX89.90 Million |
|
Willow Biosciences Inc
TO:WLLW
|
Canada | CA$3.00 Million |
|
THOR MNG CUFS/1LS- 00001
F:T5MB
|
Germany | €274.00K |
|
Agroz Inc. Ordinary Shares
NASDAQ:AGRZ
|
USA | $37.32 Million |
Liability Composition Analysis (2023–2026)
This chart breaks down Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See HKPD net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (2023–2026)
The table below shows the annual total liabilities of Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares from 2023 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | $3.26 Million | -26.34% |
| 2025-03-31 | $4.43 Million | +0.32% |
| 2024-03-31 | $4.41 Million | +56.43% |
| 2023-03-31 | $2.82 Million | -- |
About Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers customs clearance, drugs enlisting, warehouse, and other logistics services. In addition, it provides valu… Read more